News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Invasive Breast Carcinoma → cancer profile · × Clear filters
Breast cancer is surging among Asian American women — and scientists don’t know why
Breast cancer incidence is rising rapidly among Asian American women, with particularly alarming increases in younger women and in aggressive or advanced-stage disease. Researchers emphasize that improved screening alone cannot account for the surge, pointing to potentially undiscovered risk factors driving the trend. The findings highlight a critical gap in understanding racial and ethnic dispari…
Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems
A review in Nature Reviews Clinical Oncology discusses the global cancer burden using GLOBOCAN 2024 estimates: in 2024, 20.6 million people across 186 countries were diagnosed with cancer and 9.8 million died of it. Lung cancer remains the most common — 2.6 million new cases (12.8%) and 1.9 million deaths (19.1%) — ahead of female breast cancer (11.8% of cases), colorectal cancer (9.9%) and prosta…
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Adding metastasis-directed therapy (MDT — radiotherapy in 98% of lesions) to standard-of-care systemic therapy improved progression-free survival in oligometastatic disease: HR 0.54 (95% CI 0.41-0.72; P<.001) in the randomized phase 2 EXTEND trial (334 patients in the per-protocol analysis, median follow-up 53 months). The benefit persisted after excluding the two prostate baskets (HR 0.60; 95% CI…
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
The phase III randomized Skagen Trial 1 demonstrated that hypofractionated locoregional radiotherapy is a viable alternative to standard fractionation in high-risk breast cancer patients requiring regional nodal irradiation. The Danish Breast Cancer Group trial enrolled patients with node-positive or other high-risk features and compared a shorter course of radiation against the conventional fract…
Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus
An international Delphi consensus involving 36 multidisciplinary panellists from US and European oncology societies established expert agreement on patient selection and local treatment strategies for second ipsilateral breast cancer events (iBCEs) after prior breast-conserving therapy. The panel, comprising radiation oncologists, breast surgeons, a plastic surgeon, and medical physicists, complet…
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study
An independent external validation (the CATALINA study) tested whether computational tumour-infiltrating lymphocyte scoring (cTIL) matches pathologist assessment in triple-negative breast cancer. Individual data were collated from 1759 patients pooled from seven randomised adjuvant trials, of whom 1356 had complete clinicopathological data. Both pathologist-read (sTIL) and computational scores wer…
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial
In a secondary analysis of the APHINITY randomised trial in HER2-positive early breast cancer, standardised manual scoring of stromal tumour-infiltrating lymphocytes (sTILs) proved reproducible, while digital and AI-based methods delivered consistent prognostic and treatment-benefit stratification despite only modest inter-platform correlation. AI-derived spatial metrics offered complementary info…
Gedatolisib in HR+/HER2− PIK3CA wild-type breast cancer: median PFS 9.3 vs 2.0 months in phase 3
In the phase 3 VIKTORIA-1 trial (n=392), the triplet of gedatolisib, palbociclib and fulvestrant extended median progression-free survival to 9.3 months versus 2.0 months with fulvestrant alone (HR 0.24; 95% CI 0.17-0.35) in HR+/HER2− advanced breast cancer without a PIK3CA mutation, after progression on a CDK4/6 inhibitor. The objective response rate was 31.5% versus 1%, with a median duration of…
FDA Staff Raises Concerns on Breast, Prostate Cancer Drug Applications
FDA staff have raised concerns about the benefit-risk profiles of two cancer drug applications targeting breast and prostate cancer, ahead of the first Oncologic Drugs Advisory Committee (ODAC) meeting since July of last year. The advisory committee is set to convene on Thursday to evaluate both applications, despite positive clinical trial results cited by the drug sponsors. The FDA's reservation…
FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy
An FDA Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against recommending approval of a novel strategy for switching breast cancer therapy. While panel members expressed interest in the approach, they ultimately concluded that the available evidence was insufficient to support regulatory approval. The negative vote signals a significant setback for the proposed treatment-switching strategy, …